ALG-000184, Publications Extended Treatment of HBeAg+ CHB Subjects with the Capsid Assembly Modulator ALG-000184 with or without Entecavir is Associated with Reductions in Viral Markers and Favorable Anti-HBeAg trends
ALG-000184, Publications Association of Baseline Characteristics and Plasma ALG-001075 to HBsAg Responses in HBeAg+ CHB subjects following ALG-000184±ETV treatment
Preclinical, Publications In vitro and in vivo pharmacological characterization of human PNPLA3-targeting short interfering RNA molecules for the treatment of metabolic dysfunction-associated steatohepatitis
Preclinical, Publications Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles
Preclinical, Publications Second generation HBV siRNAs with novel chemistries demonstrate improved profiles compared with ALG-125755 and other clinical stage siRNAs
ALG-097558, Publications Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers
Publication, Publications An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
ALG-000184, Publications ALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects
ALG-000184, Publications ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB
ALG-000184, Publications ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB